Drug Trial Radar · NCT06720896
A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Nov 1, 2025
Primary completion
Jul 13, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Aperta Biosciences, LLCIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to its vehicle control, and to establish that the therapeutic is safe and generally well tolerated by patients.
Conditions
- Blepharitis
Interventions
APT-001 topical ophthalmic ointment (spinosad)Drug
APT-001 topical ophthalmic ointment, administered once daily
Vehicle control for APT-001 topical ophthalmic ointmentDrug
Vehicle control for APT-001 topical ophthalmic ointment, administered once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Collarette CureTime frame: From enrollment to the end of treatment at 6 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dr. Rudy Gutierrez Diaz Sede Central
Guatemala City, Guatemala
EyeScan, Imágenes Diagnósticas Oculares, S. A.
Guatemala City, Guatemala
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.